Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]

Jessica R. Bauman; Geoffrey Liu; Isabel Preeshagul; Stephen V. Liu; Barbara Melosky; Devin Abrahami; Benjamin Li; Despina Thomaidou; Kirsten Duncan; Stan Krulewicz; Martin Rupp; Jessica J. Lin

doi:10.1016/j.lungcan.2025.108441

Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]

Jessica R. Bauman
, Geoffrey Liu
, Isabel Preeshagul
, Stephen V. Liu
, Barbara Melosky
, Devin Abrahami
, Benjamin Li
, Despina Thomaidou
, Kirsten Duncan
, Stan Krulewicz
, Martin Rupp
, Jessica J. Lin

Princess Margaret Cancer Centre
Memorial Sloan-Kettering Cancer Center
Georgetown University
British Columbia Cancer Agency
Pfizer
Massachusetts General Hospital Cancer Center

Research output: Contribution to journal › Comment/debate

Abstract

The authors regret, that the following should have been added to the Acknowledgments: We would like to acknowledge funding from Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748). The authors would like to apologise for any inconvenience caused.

Original language	English
Article number	108441
Pages (from-to)	108441
Journal	Lung Cancer
Volume	201
DOIs	https://doi.org/10.1016/j.lungcan.2025.108441
State	Published - Mar 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.lungcan.2025.108441

Fingerprint

Dive into the research topics of 'Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]'. Together they form a unique fingerprint.

Cite this

Bauman, J. R., Liu, G., Preeshagul, I., Liu, S. V., Melosky, B., Abrahami, D., Li, B., Thomaidou, D., Duncan, K., Krulewicz, S., Rupp, M., & Lin, J. J. (2025). Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]. Lung Cancer, 201, 108441. Article 108441. https://doi.org/10.1016/j.lungcan.2025.108441

@article{3550785a967341568ce1724c084fdf5f,

title = "Corrigendum to {"}Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer{"} [Lung Cancer 195 (2024) 107919]",

abstract = "The authors regret, that the following should have been added to the Acknowledgments: We would like to acknowledge funding from Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748). The authors would like to apologise for any inconvenience caused.",

author = "Bauman, \{Jessica R.\} and Geoffrey Liu and Isabel Preeshagul and Liu, \{Stephen V.\} and Barbara Melosky and Devin Abrahami and Benjamin Li and Despina Thomaidou and Kirsten Duncan and Stan Krulewicz and Martin Rupp and Lin, \{Jessica J.\}",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s)",

year = "2025",

month = mar,

doi = "10.1016/j.lungcan.2025.108441",

language = "English",

volume = "201",

pages = "108441",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Bauman, JR, Liu, G, Preeshagul, I, Liu, SV, Melosky, B, Abrahami, D, Li, B, Thomaidou, D, Duncan, K, Krulewicz, S, Rupp, M & Lin, JJ 2025, 'Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]', Lung Cancer, vol. 201, 108441, pp. 108441. https://doi.org/10.1016/j.lungcan.2025.108441

Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]. / Bauman, Jessica R.; Liu, Geoffrey; Preeshagul, Isabel et al.
In: Lung Cancer, Vol. 201, 108441, 03.2025, p. 108441.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]

AU - Bauman, Jessica R.

AU - Liu, Geoffrey

AU - Preeshagul, Isabel

AU - Liu, Stephen V.

AU - Melosky, Barbara

AU - Abrahami, Devin

AU - Li, Benjamin

AU - Thomaidou, Despina

AU - Duncan, Kirsten

AU - Krulewicz, Stan

AU - Rupp, Martin

AU - Lin, Jessica J.

PY - 2025/3

Y1 - 2025/3

N2 - The authors regret, that the following should have been added to the Acknowledgments: We would like to acknowledge funding from Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748). The authors would like to apologise for any inconvenience caused.

AB - The authors regret, that the following should have been added to the Acknowledgments: We would like to acknowledge funding from Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748). The authors would like to apologise for any inconvenience caused.

UR - https://www.scopus.com/pages/publications/85218991422

U2 - 10.1016/j.lungcan.2025.108441

DO - 10.1016/j.lungcan.2025.108441

M3 - Comment/debate

C2 - 39988487

AN - SCOPUS:85218991422

SN - 0169-5002

VL - 201

SP - 108441

JO - Lung Cancer

JF - Lung Cancer

M1 - 108441

ER -

Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this